Cytokine is a type of protein that is made by certain immune and non-immune cells and has an effect on the immune system. Some cytokines stimulate the immune system and others slow it down. Cytokines can help the body fight cancer, infections, and other disorders. In cancer, cytokine therapy may help the immune system kill cancer cells or keep them from growing. The two main types of cytokines used to treat cancer are interleukins and interferons. Moreover, cytokine-based therapies have the potential to provide novel treatments for cancer, autoimmune diseases, and many types of infectious disease.

Market Statistics:

The global cytokine market is estimated to account for US$ 84,704.4 Mn in terms of value by the end of 2022.


Increase in prevalence of cancer across the globe is expected to boost the growth of the global cytokine market over the forecast period. For instance, cytokines have proven to be an effective anti-cancer therapy. In cancer, cytokine therapy may help the immune system kill cancer cells or keep them from growing. Thus, with the increase in prevalence of cancer, the use of cytokine therapy is also increasing. According to the American Cancer Society, Cancer continues to be the second most common cause of death in the United States, after heart disease. A total of 1.9 million new cancer cases and 609,360 deaths from cancer are expected to occur in the US in 2022, which is about 1,670 deaths a day.


Rising number of diagnostic, therapeutic, & prophylactic applications of cytokines is expected to offer lucrative growth opportunities for players in the global cytokine market. For instance, in May 2022, Sanofi announced that the U.S. Food and Drug Administration (FDA) accepted for priority review the supplemental Biologics License Application for Dupixent (dupilumab) to treat adults with prurigo nodularis, a chronic inflammatory skin disease that causes extreme itch and skin lesions. Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 and interleukin-13 pathways and is not an immunosuppressant.

To know the latest trends and insights prevalent in this market, click the link below:


High costs of cytokines-based therapies and lack of specificity are some major factors expected to hinder growth of the global cytokine market. Although cytokines are potentially involved in a wide range of applications such as stem cell therapy, cancer therapy, and diagnostics, the high cost of cytokines-based therapies is expected to hinder growth of the global cytokine market. Moreover, the lack of specificity can prove to be a challenge in some diagnostic cases and is a restraining factor for the growth of cytokine the market.

Global Cytokine Market - Impact of Coronavirus (Covid-19) Pandemic

According to the National Institutes of Health (NIH), some COVID-19 patients experience an immune response in which the immune system unleashes proteins that trigger inflammation, otherwise known as a cytokine storm, which can lead to acute respiratory distress syndrome, multiple organ failure and other life-threatening complications. In September 2020, Scientists at Sanford Burnham Prebys Medical Discovery Institute received a US$ 3 million grant from the NIH to study how SARS-CoV-19 weakens the immune system and identify drugs to help infected individuals recover. The major goal of the study is to learn how coronavirus (COVID-19) inactivates the antiviral cytokine pathways.

Key Takeaways:

The global cytokine market was valued at US$ 77,796.1 Mn in 2021 and is forecast to reach a value of US$ 141,667.1 Mn by 2028 at a CAGR of 8.9% between 2022 and 2028.

Among cytokine type Tumor Necrosis Factor-TNF segment held dominant position in the global cytokine market in 2021, accounting for 55.4% share in terms of value, increasing approval and launch of new products is expected to propel growth of the segment during the forecast period.

Market Trends:

  1. Increase in research and development is expected to propel the growth of the global cytokine market over the forecast period. For instance, in April 2022, Sonnet BioTherapeutics Holdings, Inc. published their data from preclinical studies of the company's proprietary Fully-Human Albumin Binding candidates, SON-1010, SON-1210, and SON-1410.
  2. Increase in product approvals is expected to drive growth of the global cytokine market over the forecast period. For instance, in June 2022, the U.S. Food and Drug Administration (FDA) approved Amgen’s RIABNI (rituximab-arrx), a biosimilar for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

Competitive Landscape:

Major players operating in the global cytokine market include

Biocon Limited, Johnson & Johnson, Abbvie Inc., UCB S.A., Astra Zeneca PLC, Sanofi SA, Pfizer Inc., Novartis International AG, Amgen Inc., and GlaxoSmithKline PLC, among others.

Recent Developments:

In September 2020, The FDA gave GlaxoSmithKline’s Nucala the green light to treat hyper-eosinophilic syndrome (HES). Nucala works by preventing protein interleukin-5 (IL-5) from binding to eosinophil cells, reducing the symptoms tied to HES.

In September 2020, Sanofi SA announced the grant of Breakthrough Therapy Designation by US Food and Drug Administration (FDA) for Dupixent (dupilumab) in the treatment of patients 12 years and above with eosinophilic esophagitis (EoE).

In March 2020, Pfizer Inc. announced the results from a Phase III study, which evaluated the safety and efficacy of abrocitinib, an investigational oral once-daily Janus kinase 1 inhibitor, in adults with moderate to severe atopic dermatitis.


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo